Introduction {#Sec1}
============

Circulating total bilirubin has been consistently shown to be inversely and independently associated with adverse cardiometabolic outcomes such as cardiovascular disease (CVD), hypertension and type 2 diabetes \[[@CR1]--[@CR3]\]. Though a causal association has been demonstrated for total bilirubin and type 2 diabetes \[[@CR4]\], there is no strong evidence for a causal association between total bilirubin levels and CVD \[[@CR5], [@CR6]\]. Nonalcoholic fatty liver disease (NAFLD), emerging as the most common cause of chronic liver disease in the developed world \[[@CR7]\], is a cardiometabolic condition which is characterized by hepatic steatosis with varying degrees of necroinflammation and fibrosis \[[@CR7]\]. In the absence of the reference standard---liver biopsy \[[@CR8]\], the diagnosis of NAFLD is commonly based on (1) imaging techniques \[i.e., ultrasonography, computed tomography (CT) scan, or magnetic resonance imaging (MRI)\] confirming the presence of fat infiltration of the liver, (2) exclusion of other liver diseases of other aetiology and (3) in the absence of substantial alcohol intake \[[@CR9]\]. Due to the high costs associated with these imaging techniques and their unsuitability for use in large-scale population-based studies, a number of biomarker-based algorithms have been developed to aid the diagnosis of NAFLD. The fatty liver index (FLI) \[[@CR10]\] and the hepatic steatosis index (HSI) \[[@CR11]\] are based on easily accessible variables and have been reported to have good diagnostic accuracies for NAFLD \[[@CR10]--[@CR12]\].

Given the existence of a strong link between total bilirubin and adverse cardiometabolic outcomes, which has been attributed to the antioxidant \[[@CR13], [@CR14]\], anti-inflammatory \[[@CR15]\] and antiatherogenic properties of bilirubin; \[[@CR16]\] there have been suggestions that circulating total bilirubin might also be associated with a reduced risk of NAFLD. Indeed, a number of observational studies have reported on the associations between bilirubin and NAFLD over recent years. However, these were based on cross-sectional or case--control study designs limited by lack of temporality, paediatric populations, selected patients with pre-existing disease or were unable to demonstrate associations specifically between total circulating bilirubin and NAFLD risk \[[@CR17]--[@CR22]\]. Therefore uncertainty remains regarding the nature and magnitude of the prospective association between total bilirubin and NAFLD. With the ongoing debate on the potential value of using circulating total bilirubin to prevent and treat cardiometabolic outcomes \[[@CR23]--[@CR25]\], it will be clinically useful if circulating total bilirubin is shown to contribute to the development of NAFLD. In this context, we aimed to quantify the nature and magnitude of the prospective association between total bilirubin and the risk of NAFLD (as estimated by these two indices---FLI and HSI) in a general population sample who were free from pre-existing disease (NAFLD, CVD, and malignancy) at baseline. Since observational epidemiological studies are beset by several biases such as residual confounding, reverse causation, and regression dilution \[[@CR26]--[@CR29]\], we utilized a Mendelian randomisation (MR) to assess if there is a causal relevance to the association using the well-known rs6742078 variant in the *UGT1A1* gene \[[@CR6], [@CR30]\].

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

We conducted this study according to STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines for reporting observational studies in epidemiology ("Appendix [1](#Sec21){ref-type="sec"}") \[[@CR31]\]. Participants for the current analysis were part of the ongoing Prevention of Renal and Vascular End-stage Disease (PREVEND) study, a large-scale general population-based observational cohort study which began in 1997 in the Netherlands. The PREVEND study was designed to investigate the natural course of urinary albumin excretion and its relationship to renal and CVD progression. The study design and recruitment procedures have been described in detail in several previous reports \[[@CR2], [@CR32]\]. Briefly, 8592 inhabitants aged 28--75 years living in the city of Groningen, the Netherlands were recruited into the PREVEND study with baseline measurements performed between 1997 and 1998. For the present analysis, we excluded participants (1) with a prevalent history of CVD, renal disease, malignancy, or NAFLD (for the analysis of FLI outcome, participants with prevalent NAFLD as measured by FLI were excluded and vice versa for HSI) and (2) with excessive alcohol use (defined as four or more drinks per day), which left a cohort of 3824 participants (based on FLI) with non-missing information on total bilirubin levels, relevant covariates, and outcomes. Of these participants, 1610 individuals had complete phenotypic and genotypic data. The PREVEND study complies with the Declaration of Helsinki and was approved by the medical ethics committee of the University Medical Center Groningen. All participants provided written informed consent for voluntary participation.

Risk factor assessment {#Sec4}
----------------------

For the assessment of baseline data on sociographic characteristics, physical measurements, medical history, and use of medication, participants completed two outpatient visits. Further information on medication use was complemented using data from all community pharmacies in the city of Groningen and this covers complete information on drug use in 95% of PREVEND participants. Venous blood was obtained from participants after an overnight fast and 15 min of rest. Plasma samples were prepared by centrifugation at 4 °C. Blood lipids (total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGs)), high sensitivity C-reactive protein (hsCRP), serum creatinine, and serum cystatin C were measured using standard laboratory protocols previously described \[[@CR33]--[@CR35]\]. Total bilirubin was measured using a colorimetric assay (2,4-dicholoraniline reaction; Merck MEGA, Darmstadt, Germany), with the detection limit being 1.0 µmol/L. The inter-assay coefficients of variation were 3.8% and 2.9% in the lower normal and higher normal range respectively. The mean of two 24-h urine collections was used to estimate urinary albumin excretion (UAE) and its concentration determined by nephelometry (BNII; Dade Behring Diagnostic, Marburg, Germany). Serum liver aminotransferase (alanine aminotransferase, ALT and aspartate aminotransferase, AST) activities were measured using the standardized kinetic method with pyridoxal phosphate activation (Roche Modular P; Roche Diagnostics, Mannheim, Germany). Serum gamma-glutamyltransferase (GGT) activity was measured by an enzymatic colorimetric method (Roche Modular P; Roche Diagnostics, Mannheim, Germany). Estimated glomerular filtration rate (eGFR), was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) combined creatinine-cystatin C equation \[[@CR36]\]. Body mass index (BMI) was estimated by dividing weight measured in kilograms by the square of height in meters.

NAFLD ascertainment {#Sec5}
-------------------

The FLI was calculated based on the report by Bedogni et al. \[[@CR10]\] using the following formula:$$\documentclass[12pt]{minimal}
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The FLI ranges from 0 to 100, with FLI \< 30 ruling out (sensitivity = 87%) and FLI ≥ 60 ruling in fatty liver disease (specificity = 86%) with a good diagnostic accuracy of 0.84 (95% CI 0.81--0.87).

The HSI was estimated using the following formula as reported by Lee et al.: \[[@CR11]\]$$\documentclass[12pt]{minimal}
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Genotyping {#Sec6}
----------

Genotyping was performed using Illumina HumanCytoSNP-12 arrays. SNPs were called using Illumina Genome Studio software. SNPs were excluded with minor allele frequency \< 0.01, call rate \< 0.95, or deviation from Hardy--Weinberg equilibrium (*p *\< 1×10 − 5). The rs6742078 SNP was a suitable instrumental variable for the present analyses, given its robust specificity for circulating total bilirubin levels (explaining up to 45% of the variation in circulating bilirubin levels \[[@CR37]\]) and its use in previous studies to assess the causal relevance of total bilirubin to several disease outcomes \[[@CR5], [@CR6], [@CR30]\].

Statistical analyses {#Sec7}
--------------------

### Observational analyses {#Sec8}

Skewed variables (total bilirubin, ALT, AST, TGs, hsCRP, and UAE) were natural log-transformed to approximate normal distributions. Descriptive analyses were used to summarize baseline characteristics of participants overall and according to NAFLD outcomes. Partial correlation coefficients adjusted for age and sex were calculated to assess cross-sectional associations of total bilirubin levels with risk markers for NAFLD. Logistic regression was used to examine the association of total bilirubin with new-onset NAFLD as measured by FLI or HSI (observed effect of bilirubin on NAFLD). The odds ratio (OR) with 95% confidence intervals (CIs) for the risk of NAFLD was calculated per 1 standard deviation, SD higher log~e~ total bilirubin levels. In subsidiary analyses, total bilirubin was modeled as tertiles defined according to its baseline distribution. The SD of baseline log~e~ total bilirubin level was 0.42 (equivalent to 1.5-fold higher circulating total bilirubin level, as e^0.42^ = 1.52). Odds ratios were progressively adjusted for in four models: (Model 1) age and sex; (Model 2) plus smoking status, systolic blood pressure (SBP), total cholesterol, and HDL-C; (Model 3) plus alcohol consumption, glucose, eGFR, and UAE; and (Model 4) plus hsCRP. Confounders were selected based on their known associations with NAFLD and observed associations with total bilirubin using the available data \[[@CR38]\] and evidence from previous research \[[@CR1], [@CR2]\]. We used interaction tests to assess statistical evidence of effect modification by sex on the association. To minimise bias due to potential reverse causation, we carried out sensitivity analyses that excluded participants with a history of diabetes at baseline, participants on regular statin medication or participants with potential Gilbert's syndrome (defined as defined as total bilirubin \> 34.2 µmol/L, AST \< 80 IU/L, ALT \< 80 IU/L, and GGT \< 80 IU/L) \[[@CR1]\].

### Mendelian randomization {#Sec9}

To assess for pleiotropy, we tested whether rs6742078 was associated with relevant risk markers which might confound the relationship between total bilirubin and NAFLD. We assessed the association between rs6742078 and log~e~ total bilirubin using linear regression under the assumption of an additive genetic model, with adjustment for covariates used in the observational analysis between total bilirubin and NAFLD. This analysis provided the number of SDs above log~e~ total bilirubin per each copy increase in number of the T allele. In order to estimate the causal effect of bilirubin on NAFLD, we used the two-stage least squares (2SLS) method. The first stage of the 2SLS method is to examine the association between rs6742078 and total bilirubin by means of linear regression (model 1) and then saving the predicted values and the residuals. In the second stage, the predicted values of total bilirubin from model 1 are used as covariates, with NAFLD as a dependent variable in a logistic regression, which provides the MR estimate. Estimates of power for the MR analysis on NAFLD employed an online power calculator (\[http:/cnsgenomics.com/shiny/mRnd/\]). We used the genetic sample size and case/control ratios together with the proportion of variance of total bilirubin explained by rs6742078. Using PREVEND data, we had 20% power to detect a causal association of bilirubin on NAFLD, similar in magnitude to the fully adjusted observational OR of 0.82. All statistical analyses were conducted using Stata version 15 (Stata Corp, College Station, Texas, USA).

Results {#Sec10}
=======

Baseline characteristics and correlates of total bilirubin {#Sec11}
----------------------------------------------------------

Baseline descriptive characteristics of study participants as well as cross-sectional correlates of total bilirubin are shown in Table [1](#Tab1){ref-type="table"}. The overall mean age of participants at study entry was 47 (SD 12) years and 40.6% were women. The mean (SD) of log~e~ total bilirubin level was 1.96 (0.42) µmol/l. There were weak and inverse correlations of log~e~ total bilirubin levels with physical measures (BMI and waist circumference), lipids (total cholesterol and TGs), and glucose. There were weak positive correlations with HDL-C and the liver aminotransferases. There was an inverse correlation with log~e~ hsCRP (r = − 0.24). Baseline total bilirubin levels were higher by 28% in men compared with women. The levels were lower by 12% in the combined group of current and former smokers compared with non-current smokers (Table [2](#Tab2){ref-type="table"}). "Appendices [2](#Sec22){ref-type="sec"}--[3](#Sec23){ref-type="sec"}" show baseline characteristics according to the development of NAFLD. Except for history of diabetes and smoking status, there were significant differences in baseline clinically relevant subgroups and levels of risk markers between participants who did and did not develop NAFLD (for both indices) during follow-up.Table 1Baseline characteristics and cross-sectional correlates of total bilirubinOverall (*N* = 3824)\
Mean (SD) or median (IQR) or n (%)Partial correlation\
r (95% CI)^a^Percentage difference (95% CI) in total bilirubin levels per 1 SD higher or compared to reference category of correlate^b^Total bilirubin (µmol/l)7 (5--9)----Sex Female2273 (59.4)--Ref Male1551 (40.6)--28% (25, 31)\*\*\**Questionnaire*Age at survey (years)47 (12)− 0.02 (− 0.06, 0.01)− 1% (− 2, 0)History of diabetes No3801 (99.4)--Ref Yes23 (0.6)--− 8% (− 22, 8)Smoking status Non-smokers1309 (34.2)--Ref Current and former smokers2515 (65.8)--− 12% (− 14, − 9)\*\*\*Alcohol consumption Non-consumers886 (23.2)--Ref Current consumers2938 (76.8)--3% (0, 7)\**Physical measurements*BMI (kg/m^2^)24.4 (2.8)− 0.11 (− 0.15, − 0.09)\*\*\*− 5% (− 6, − 3)\*\*\*Waist circumference (cm)82.6 (9.5)− 0.08 (− 0.11, − 0.05)\*\*\*− 4% (− 5, − 2)\*\*\*SBP (mmHg)123 (18)− 0.01 (− 0.04, 0.02)− 1% (− 2, 1)DBP (mmHg)71 (9)− 0.03 (− 0.06, 0.00)− 1% (− 3, 0)*Lipid, metabolic, inflammatory, liver, and renal markers*Total cholesterol (mmol/l)5.44 (1.07)− 0.09 (− 0.13, − 0.06)\*− 4% (− 5, − 3)\*HDL-C (mmol/l)1.43 (0.39)0.10 (0.07, 0.13)\*\*\*5% (3, 6)\*\*\*Triglycerides (mmol/l)0.98 (0.75--1.31)− 0.15 (− 0.18, − 0.12)\*\*\*6% (− 7, − 5)\*\*\*Glucose (mmol/l)4.60 (0.73)− 0.05 (− 0.08, − 0.02)\*− 2% (− 3, − 1)\*GGT (U/L)19 (14--27)− 0.02 (− 0.05, 0.01)− 1% (− 2, 0)ALT (U/L)18 (14--23)0.03 (0.00, 0.06)\*1% (0, 3)\*AST (U/L)23 (20--27)0.09 (0.06, 0.13)\*\*\*4% (3, 6)\*\*\*hsCRP (mg/l)0.90 (0.41--2.12)− 0.24 (− 0.27, − 0.21)\*\*\*− 9% (− 10, − 8)\*\*\*eGFR (ml/min/1.73 m^2^)90.8 (15.0)− 0.01 (− 0.04, 0.02)− 0% (− 2, 1)UAE (mg/24 h)8.14 (5.91--12.53)− 0.01 (− 0.04, 0.03)1% (− 1, 2)*ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *BMI* body mass index, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), *GGT* gamma-glutamyltransferase, *HDL-C* high-density lipoprotein cholesterol, *hsCRP* high-sensitivity C-reactive protein, *Ref* reference, *SD* standard deviation, *SBP* systolic blood pressure, *UAE* urinary albumin excretion^a^Partial correlation coefficients between log~e~ total bilirubin and each of the row variables adjusted for age and sex^b^Percentage change in total bilirubin levels per 1 SD increase in the row variable (or for categorical variables, the percentage difference in mean total bilirubin levels for the category versus the reference) adjusted for age and sexAsterisks indicate the level of statistical significance: \* *p* \< 0.05; \*\* *p* \< 0.01; \*\*\* *p* \< 0.001Table 2Association of baseline total bilirubin with incident NAFLD as measured by FLITotal bilirubin level (µmol/l)Events/totalModel 1Model 2Model 3Model 4OR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valuePer 1 SD increase434/38240.72 (0.64 to 0.80)\< 0.0010.78 (0.69 to 0.87)\< 0.0010.77 (0.69 to 0.87)\< 0.0010.82 (0.73 to 0.92)0.001T1 (0.95--6)208/1627Ref.Ref.Ref.Ref.T2 (7, 8)116/10240.70 (0.55 to 0.90)0.0060.85 (0.65 to 1.10)0.2090.85 (0.66 to 1.11)0.2320.92 (0.71 to 1.20)0.536T3 (≥ 9)110/11730.51 (0.39 to 0.66)\< 0.0010.62 (0.47 to 0.81)\< 0.0010.61 (0.47 to 0.80)\< 0.0010.69 (0.52 to 0.91)0.0082420 participants with prevalent NAFLD as measured by FLI were excluded*CI* confidence interval, *FLI* fatty liver index, *NAFLD* non-alcoholic fatty liver disease, *OR* odds ratio, *SD* standard deviation, *T* tertileModel 1: Age and sexModel 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterolModel 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and log~e~ urinary albumin excretionModel 4: Model 3 plus log~e~ high-sensitivity C-reactive protein

Total bilirubin levels and risk of incident NAFLD {#Sec12}
-------------------------------------------------

During a mean (SD) follow-up of 4.2 (0.4) years, 434 and 452 cases of NAFLD as estimated by FLI and HSI respectively, were recorded. The associations between total bilirubin and NAFLD as estimated by the FLI are reported in Table [2](#Tab2){ref-type="table"}. In age and sex adjusted analysis, the OR for NAFLD (as estimated by FLI) per 1 SD change in log~e~ total bilirubin was 0.72 (95% CI 0.64--0.80; *p *\< 0.001), which was minimally attenuated to 0.77 (95% CI 0.69--0.87; *p *\< 0.001) after further adjustment for several established and emerging risk factors. Following additional adjustment for hsCRP, the OR was 0.82 (95% CI 0.73--0.92; *p *\< 0.001). In analyses that compared the top versus bottom tertiles of total bilirubin, the inverse associations between total bilirubin and NAFLD were evident (Table [2](#Tab2){ref-type="table"}).

Odds ratios for the associations between total bilirubin and NAFLD as estimated by the HSI are reported in Table [3](#Tab3){ref-type="table"}. The age- and sex-adjusted OR for NAFLD per 1 SD change in log~e~ total bilirubin was 0.79 (95% CI 0.72--0.88; *p *\< 0.001), which remained consistent 0.84 (95% CI 0.75--0.93; *p *= 0.001) following further adjustment for several established and emerging risk factors. Following additional adjustment for hsCRP, the OR was 0.87 (95% CI 0.78--0.97; *p *= 0.012). In analyses that compared the top versus bottom tertiles of total bilirubin, the inverse associations remained except for evidence of attenuation to the null on further adjustment for hsCRP (Table [2](#Tab2){ref-type="table"}).Table 3Association of baseline total bilirubin with incident NAFLD as measured by HSITotal bilirubin level (µmol/l)Events/totalModel 1Model 2Model 3Model 4OR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valuePer 1 SD increase452/35700.79 (0.72 to 0.88)\< 0.0010.83 (0.75 to 0.93)0.0010.84 (0.75 to 0.93)0.0010.87 (0.78 to 0.97)0.012T1 (0.95--6)229/1476Ref.Ref.Ref.Ref.T2 (7, 8)107/9670.67 (0.53 to 0.86)0.0020.75 (0.58 to 0.97)0.0260.77 (0.60 to 0.99)0.0410.80 (0.62 to 1.04)0.094T3 (≥ 9)116/11270.63 (0.49 to 0.81)\< 0.0010.71 (0.55 to 0.92)0.0090.73 (0.56 to 0.94)0.0140.78 (0.61 to 1.02)0.0662801 participants with prevalent NAFLD as measured by HSI were excluded*CI* confidence interval, *HSI* hepatic steatosis index, *NAFLD* non-alcoholic fatty liver disease, *OR* odds ratio, *SD* standard deviation, *T* tertileModel 1: Age and sexModel 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterolModel 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and log~e~ urinary albumin excretionModel 4: Model 3 plus log~e~ high-sensitivity C-reactive protein

The association between total bilirubin and NAFLD was not statistically significantly modified by sex for both measures of NAFLD (*p *\> 0.05); whereas the association between total bilirubin and NAFLD (as estimated by FLI) was comparable in males and females, the age-adjusted inverse association between total bilirubin and NAFLD (as estimated by HSI) in males was attenuated to null on further adjustment for established risk factors (Table [4](#Tab4){ref-type="table"}). The ORs for all associations remained similar in sensitivity analyses that involved exclusion of participants with prevalent diabetes, participants on cholesterol lowering medication, or participants with potential Gilbert's syndrome ("Appendices [4](#Sec24){ref-type="sec"}--[5](#Sec25){ref-type="sec"}").Table 4Association of baseline total bilirubin with incident NAFLD in males and femalesGenderEvents/totalModel 1Model 2Model 3Model 4OR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* value*NAFLD as measured by Fatty Liver Index*Males253/15510.71 (0.62 to 0.82)\< 0.0010.80 (0.68 to 0.92)0.0020.79 (0.68 to 0.92)0.0020.81 (0.69 to 0.94)0.007Females181/22730.71 (0.59 to 0.85)\< 0.0010.75 (0.63 to 0.90)0.0020.75 (0.63 to 0.90)0.0020.83 (0.69 to 1.00)0.055*NAFLD as measured by Hepatic Steatosis Index*Males358/15910.84 (0.72 to 0.97)0.0200.92 (0.80 to 1.08)0.3080.94 (0.81 to 1.09)0.4070.95 (0.81 to 1.11)0.527Females91/19080.74 (0.64 to 0.86)\< 0.0010.76 (0.65 to 0.88)\< 0.0010.76 (0.65 to 0.88)\< 0.0010.81 (0.69 to 0.94)0.006*CI* confidence interval, *NAFLD* non-alcoholic fatty liver disease, *OR* odds ratio, *SD* standard deviation, ORs are reported per 1-SD increase in log~e~ total bilirubinModel 1: AgeModel 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterolModel 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and log~e~ urinary albumin excretionModel 4: Model 3 plus log~e~ high-sensitivity C-reactive protein

Mendelian randomization findings {#Sec13}
--------------------------------

There was strong evidence for an association between rs6742078 SNP and total bilirubin (0.70 SD increase in total bilirubin levels per T allele; SE = 0.03, *p *= 1.35 × 10^−80^) and the SNP explained 20% of total variance in total bilirubin levels. There was no evidence for associations between rs6742078 and confounders included in the observational analyses, except for a weak association with sex ("Appendix [6](#Sec26){ref-type="sec"}"). The causal OR for FLI was 0.98 (95% CI 0.69--1.38; *p *= 0.900) per 1 SD genetically elevated total bilirubin level and that for HSI was 1.14 (95% CI 0.81--1.59; *p *= 0.451) (Table [5](#Tab5){ref-type="table"}).Table 5Causal estimates for NAFLD (as measured by FLI and HSI) using Mendelian randomisation analysisNAFLD outcomeEvents/totalUnadjusted OR (95% CIs)*p* valueAdjusted^a^ OR (95% CIs)*p* valueFLI187/16100.98 (0.69 to 1.38)0.9000.99 (0.70 to 1.42)0.978HSI190/15281.14 (0.81 to 1.59)0.4511.10 (0.79 to 1.54)0.556*CI* confidence interval, *FLI* fatty liver index, *HSI* hepatic steatosis index, *NAFLD* non-alcoholic fatty liver disease, *OR* odds ratio^a^Model adjusted for age, sex, smoking status, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, alcohol consumption, glucose, estimated glomerular filtration rate, log~e~ urinary albumin excretion, log~e~ high-sensitivity C-reactive protein

Comments {#Sec14}
========

Key findings {#Sec15}
------------

Using a large-scale population-based study of predominantly Caucasian men and women without pre-existing disease including NAFLD at baseline, we have demonstrated that total bilirubin is inversely associated with future risk of NAFLD as estimated by two well-known biomarker indices, the FLI and HSI respectively. The associations were independent of several established risk factors and other potential confounders and remained robust in several sensitivity analyses. The inverse association between total bilirubin and NAFLD was not significantly modified by sex. However, given the rather relatively small numbers (low event rates) in males and females, larger-scale studies in both genders are needed to further evaluate a potential role of sex on the impact of bilirubin on new onset NAFLD. Furthermore, using a MR analysis, we investigated whether the observed association between total bilirubin and NAFLD was devoid of confounding and/or reverse causation. Despite strong observational evidence for associations between bilirubin and NAFLD, these results were not supported by MR analyses---there was no evidence for a causal relationship between genetically elevated bilirubin and NAFLD. While the rs6742078 SNP was strongly associated with levels of circulating bilirubin and the F statistic (\> 400) indicated good instrument strength, the observed wide 95% CIs for the MR results are indicative of low power. For MR to be valid, several assumptions need to be met: \[[@CR39]\] the genetic instrument (1) must be associated with the exposure of interest, (2) must not be associated with any confounders and (3) must not directly influence the outcome, except through the exposure of interest. When exploring the association between rs6742078 and confounding variables included in the observational analyses, no evidence for associations was found, except for weak evidence of an association between rs6742078 and sex. While this could be a chance finding, given the multiple tests that were performed, it is also possible that this might represent a true causal relationship. This might reflect the sex differences in hepatic uridine diphosphate glucuronyltransferase (UGT1A1) activity \[[@CR40]\], the enzyme that contributes substantially to bilirubin glucuronidation and enhances bilirubin elimination. Consistent with our findings, previous studies have demonstrated higher levels of circulating bilirubin in men compared with women \[[@CR19]\]. On the contrary, a number of studies have reported findings which suggest that the discordance in circulating bilirubin levels between males and females may not be attributable to differences in the UGT1A1 polymorphism \[[@CR41]--[@CR43]\]. Therefore, these findings deserve follow-up in larger cohort studies.

Comparison with previous studies {#Sec16}
--------------------------------

A limited number of epidemiological observational studies have reported on the associations of bilirubin with the risk of NAFLD. In an analysis of over 17,000 participants, Kwak et al. demonstrated an inverse association between total bilirubin and NAFLD diagnosed on the basis of ultrasonographic findings and an alcohol consumption of less than 20 g/day \[[@CR19]\]. However, the main limitation of this study was its cross-sectional design, which precluded the ability to assess the temporal relationship between bilirubin and the risk of NAFLD. Findings from two prospective cohort studies have demonstrated serum direct bilirubin to be associated with reduced risk of NAFLD, but found no evidence of associations for total or indirect bilirubin \[[@CR17], [@CR20]\]. To our knowledge, this is the first study to demonstrate a long-term prospective association between total bilirubin and the risk of NAFLD in a general predominantly Caucasian population. We are also the first to investigate whether a potential causal association exists between elevated total bilirubin levels and decreased NAFLD risk in a general adult population. Furthermore, our study employed NAFLD outcomes diagnosed on the basis of biomarker-based indices, whereas previous relevant studies have utilized ultrasonographic findings \[[@CR17]--[@CR20]\].

Potential explanations for findings {#Sec17}
-----------------------------------

Bilirubin, iron and carbon monoxide are degradation products of heme catabolism via heme oxygenase-1 (HO-1) and they have been reported to regulate important functions in cells \[[@CR44]\]. Increasing evidence suggests that bilirubin has cytoprotective properties \[[@CR45]\], antioxidant actions \[[@CR13], [@CR14]\] and anti-inflammatory effects via its anti-complement actions \[[@CR15], [@CR46]\]. Since oxidative stress mechanisms and inflammation play a major role in the pathophysiology of NAFLD \[[@CR47], [@CR48]\], if there is a protective effect of bilirubin on NAFLD risk, this may be via the potent antioxidant and anti-inflammatory effects of bilirubin. Whether total bilirubin is a direct cause of NAFLD or just a risk marker of underlying NAFLD, is not certain at the moment. Our MR findings did not provide evidence for a causal association between circulating total bilirubin and NAFLD. It may be possible that the observational association may be driven by biases such as unmeasured confounding and/or reverse causation. The current evidence suggests that total bilirubin may just be a risk marker of NAFLD. However, given that the MR estimates were under-powered and a causal effect of bilirubin on NAFLD cannot be completely ruled out, further investigation in a larger sample is necessary.

Implications of findings {#Sec18}
------------------------

The current findings further contribute to the accumulating body of evidence on the putative protective role of bilirubin on adverse cardiometabolic outcomes such as hypertension, diabetes, metabolic syndrome and CVD \[[@CR1]--[@CR4]\]. Indeed, the utility of using circulating bilirubin to prevent and treat cardiometabolic disease has been extensively debated \[[@CR23]--[@CR25]\]. It is reported that patients with Gilbert syndrome (characterised by moderate hyperbilirubinaemia) have reduced levels of markers of oxidative stress and inflammation and have decreased risk of vascular complications; \[[@CR49], [@CR50]\] hence, it is possible that the sustained hyperbilirubinaemia prevents vascular complications via inhibition of oxidative stress and inflammation. Circulating bilirubin is a simple, standardised, cheap, and easily measured biomarker, hence its potential value in reducing the risk of adverse cardiometabolic outcomes warrants further evaluation.

Strengths and limitations {#Sec19}
-------------------------

In addition to the novelty, several strengths of this work deserve mention. These include employing a sample that was representative of the general population, exclusion of participants with pre-existing disease which minimised biases due to reverse causation, accounting for several key clinical characteristics, and conducting several sensitivity analyses to confirm the robustness of the findings. In our MR analysis, we used the rs6742078 variant to examine the potential causal relationship, which has been shown to be strongly associated with substantial increases in levels of bilirubin and explained substantial proportion of variation in bilirubin levels. The limitations of the current work include the inability to generalise the findings to other populations as the sample predominantly comprised of white adults of Dutch descent, absence of data on repeat measurements of bilirubin to correct for regression dilution bias, and inability to replicate or verify the findings in an independent cohort due to lack of data. One might say that the association between rs6742078 and sex violated one of the conditions for the MR analysis, hence impacting on the causal estimates. However, this is unlikely for the following reasons: (1) the association was weak and (2) it is very likely this was a chance finding (due to the multiple statistical tests) given that the rs6742078 variant has consistently been demonstrated to be very specific for bilirubin and is not associated with various demographics (including sex), lifestyle and clinical variables in several MR studies \[[@CR5], [@CR6], [@CR30]\] and including the PREVEND cohort \[[@CR4]\] which was employed for these analyses. In addition, the power to detect an effect similar to the observational estimates was low and larger samples (with higher number of cases) are required. In addition, the availability of large samples for genome-wide association study, such as UK Biobank \[[@CR51]\], will increase the discovery of genetic variants, which will in turn provide better instruments for MR analyses.

Conclusion {#Sec20}
==========

Elevated circulating total bilirubin was independently associated with decreased risk of new onset NAFLD in a cohort of apparently healthy predominantly Caucasian men and women without pre-existing CVD or NAFLD. Based on MR analysis, there was little evidence to suggest a causal association. The observational association may be driven by biases such as unmeasured confounding and/or reverse causation. However, due to low statistical power, larger-scale investigations are necessary to draw definitive conclusions.
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See Table [6](#Tab6){ref-type="table"}.Table 6STROBE 2007 Statement---Checklist of items that should be included in reports of cohort studiesSection/topicItem \#RecommendationReported on page \#*Title and abstract*1(a) Indicate the study's design with a commonly used term in the title or the abstractPage 1(b) Provide in the abstract an informative and balanced summary of what was done and what was foundPage 2*Introduction*Background/rationale2Explain the scientific background and rationale for the investigation being reportedPage 3Objectives3State specific objectives, including any prespecified hypothesesPage 3--4*Methods*Study design4Present key elements of study design early in the paperStudy populationSetting5Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collectionStudy populationParticipants6(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-upStudy population(*b*) For matched studies, give matching criteria and number of exposed and unexposedNot applicableVariables7Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicableRisk Factor AssessmentData sources/measurement8\*For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one groupRisk Factor AssessmentBias9Describe any efforts to address potential sources of biasStatistical MethodsStudy size10Explain how the study size was arrived atStatistical MethodsQuantitative variables11Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and whyStatistical MethodsStatistical methods12(a) Describe all statistical methods, including those used to control for confoundingStatistical Methods(b) Describe any methods used to examine subgroups and interactionsStatistical Analyses(c) Explain how missing data were addressedNot applicable(d) If applicable, explain how loss to follow-up was addressedNot applicable(e) Describe any sensitivity analysesStatistical Methods*Results*Participants13\*(a) Report numbers of individuals at each stage of study---e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysedStudy population(b) Give reasons for non-participation at each stageStudy population(c) Consider use of a flow diagramDescriptive data14\*(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confoundersResults; Table [1](#Tab1){ref-type="table"}; "Appendices [2](#Sec22){ref-type="sec"}--[3](#Sec23){ref-type="sec"}"(b) Indicate number of participants with missing data for each variable of interest(c) Summarise follow-up time (e.g. average and total amount)ResultsOutcome data15\*Report numbers of outcome events or summary measures over timeResultsMain results16(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were includedResults; Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}(*b*) Report category boundaries when continuous variables were categorizedResults; Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time periodOther analyses17Report other analyses done---e.g. analyses of subgroups and interactions, and sensitivity analysesResults; "Appendices [4](#Sec24){ref-type="sec"}--[5](#Sec25){ref-type="sec"}"*Discussion*Key results18Summarise key results with reference to study objectivesDiscussion---Summary of main findings*Limitations*Interpretation20Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidenceDiscussionGeneralisability21Discuss the generalisability (external validity) of the study resultsDiscussion*Other informationFunding*22Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is basedPages 14--15
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See Table [7](#Tab7){ref-type="table"}.Table 7Baseline participant characteristics according to the development of NAFLD as measured by FLIWithout NAFLD (N = 3390)\
Mean (SD) or median (IQR) or n (%)With NAFLD (N = 434)\
Mean (SD) or median (IQR) or n (%)*p* value\*Total bilirubin (µmol/l)7 (5--9)7 (5--9)\< 0.001*Questionnaire*Males1298 (38.3)253 (58.3)\< 0.001Age at survey (years)47 (12)50 (12)\< 0.001History of diabetes18 (0.5)5 (1.2)0.115Current and former smokers2212 (65.3)303 (69.8)0.059Alcohol consumers2606 (76.9)332 (76.5)0.861*Physical measurements*BMI (kg/m^2^)24.1 (2.7)27.1 (2.5)\< 0.001Waist circumference (cm)81.5 (9.3)90.9 (7.0)\< 0.001SBP (mmHg)122 (17)131 (18)\< 0.001DBP (mmHg)71 (9)75 (9)\< 0.001*Lipid, metabolic, inflammatory, liver, and renal markers*Total cholesterol (mmol/l)5.40 (1.07)5.80 (1.02)\< 0.001HDL-C (mmol/l)1.45 (0.39)1.22 (0.32)\< 0.001Triglycerides (mmol/l)0.95 (0.73--1.26)1.23 (0.96--1.61)\< 0.001Glucose (mmol/l)4.57 (0.72)4.85 (0.76)\< 0.001GGT (U/L)18 (14--25)26 (19--36)\< 0.001ALT (U/L)18 (14--23)21 (16--28)\< 0.001AST (U/L)23 (20--26)24 (21--28)\< 0.001hsCRP (mg/l)0.84 (0.38--1.96)1.49 (0.75--3.05)\< 0.001eGFR (ml/min/1.73 m^2^)91.2 (15.0)87.3 (15.0)\< 0.001UAE (mg/24 h)7.99 (5.84--12.30)9.42 (6.53--14.61)\< 0.001*ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *BMI* body mass index, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), *FLI* fatty liver index, *GGT* gamma-glutamyltransferase, *HDL-C* high-density lipoprotein cholesterol, *hsCRP* high-sensitivity C-reactive protein, *NAFLD* non-alcoholic fatty liver disease\*Employed a two-sample *t*-tests for a difference in means for continuous variables and a Chi square test for categorical variables

Appendix 3 {#Sec23}
==========

See Table [8](#Tab8){ref-type="table"}.Table 8Baseline participant characteristics according to the development of NAFLD as measured by HSIWithout NAFLD (N = 3118)\
Mean (SD) or median (IQR) or n (%)With NAFLD (N = 452)\
Mean (SD) or median (IQR) or n (%)*p* value\*Total bilirubin (µmol/l)7 (6--9)6 (5--9)\< 0.001*Questionnaire*Males1432 (45.9)195 (43.1)0.266Age at survey (years)47 (12)48 (12)0.101History of diabetes11 (0.4)2 (0.4)0.767Current and former smokers2116 (67.9)306 (67.7)0.944Alcohol consumers2459 (78.9)322 (71.2)\< 0.001*Physical measurements*BMI (kg/m^2^)23.7 (2.4)26.1 (2.0)\< 0.001Waist circumference (cm)81.8 (10.0)87.9 (9.5)\< 0.001SBP (mmHg)123 (18)128 (19)\< 0.001DBP (mmHg)72 (9)73 (9)\< 0.001*Lipid, metabolic, inflammatory, liver, and renal markers*Total cholesterol (mmol/l)5.43 (1.08)5.69 (1.10)\< 0.001HDL-C (mmol/l)1.43 (0.40)1.33 (0.38)\< 0.001Triglycerides (mmol/l)0.99 (0.74--1.36)1.15 (0.85--1.63)\< 0.001Glucose (mmol/l)4.58 (0.70)4.74 (1.07)\< 0.001GGT (U/L)19 (14--27)21 (14--31)\< 0.001ALT (U/L)17 (14--22)19 (15--25)\< 0.001AST (U/L)23 (20--27)23 (20--28)0.023hsCRP (mg/l)0.84 (0.37--1.99)1.26 (0.62--2.69)\< 0.001eGFR (ml/min/1.73 m^2^)90.8 (15.3)88.9 (15.1)0.016UAE (mg/24 h)8.28 (5.96--13.13)8.57 (6.13--12.91)0.423*ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *BMI* body mass index, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), *GGT* gamma-glutamyltransferase, *HDL-C* high-density lipoprotein cholesterol, *hsCRP* high-sensitivity C-reactive protein, *HSI* hepatic steatosis index, *NAFLD* non-alcoholic fatty liver disease\*Employed a two-sample *t*-tests for a difference in means for continuous variables and a Chi square test for categorical variables

Appendix 4 {#Sec24}
==========

See Table [9](#Tab9){ref-type="table"}.Table 9Association of baseline serum total bilirubin levels with FLI in several sensitivity analysesEvents/totalModel 1Model 2Model 3Model 4OR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valueExclusion of people with diabetes at baseline429/38010.71 (0.63 to 0.79)\< 0.0010.77 (0.69 to 0.86)\< 0.0010.77 (0.68 to 0.86)\< 0.0010.81 (0.72 to 0.92)0.001Exclusion of people on cholesterol lowering medication416/37130.71 (0.64 to 0.80)\< 0.0010.77 (0.69 to 0.87)\< 0.0010.77 (0.68 to 0.87)\< 0.0010.82 (0.73 to 0.92)0.001Exclusion of people with potential Gilbert's disease434/38200.72 (0.64 to 0.80)\< 0.0010.78 (0.69 to 0.88)\< 0.0010.78 (0.69 to 0.87)\< 0.0010.82 (0.73 to 0.93)0.001Gilbert's disease was defined as total bilirubin \> 34.2 µmol/L, aspartate aminotransferase \< 80 IU/L, alanine aminotransferase \< 80 IU/L, and gamma-glutamyltransferase \< 80 IU/L2420 participants with prevalent NAFLD as measured by FLI were excluded*CI* confidence interval, *FLI* fatty liver index, *NAFLD* non-alcoholic fatty liver disease, *OR* odds ratio, *SD* standard deviation, *T* tertileModel 1: Age and sexModel 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterolModel 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and log~e~ urinary albumin excretionModel 4: Model 3 plus log~e~ high-sensitivity C-reactive protein
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See Table [10](#Tab10){ref-type="table"}.Table 10Association of baseline serum total bilirubin levels with HSI in several sensitivity analysesEvents/totalModel 1Model 2Model 3Model 4OR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valueOR (95% CI)*p* valueExclusion of people with diabetes at baseline450/35570.79 (0.71 to 0.88)\< 0.0010.83 (0.75 to 0.92)0.0010.84 (0.75 to 0.93)0.0010.87 (0.78 to 0.97)0.011Exclusion of people on cholesterol lowering medication430/34530.81 (0.73 to 0.90)\< 0.0010.86 (0.77 to 0.96)0.0050.87 (0.77 to 0.96)0.0080.89 (0.80 to 1.00)0.041Exclusion of people with potential Gilbert's disease452/35660.79 (0.72 to 0.88)\< 0.0010.83 (0.75 to 0.93)0.0010.84 (0.75 to 0.94)0.0020.87 (0.78 to 0.97)0.014Gilbert's disease was defined as total bilirubin \> 34.2 µmol/L, aspartate aminotransferase \< 80 IU/L, alanine aminotransferase \< 80 IU/L, and gamma-glutamyltransferase \< 80 IU/L2801 participants with prevalent NAFLD as measured by HSI were excluded*CI* confidence interval, *HSI* hepatic steatosis index, *NAFLD* non-alcoholic fatty liver disease, *OR* odds ratio, *SD* standard deviation, *T* tertileModel 1: Age and sexModel 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterolModel 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and log~e~ urinary albumin excretionModel 4: Model 3 plus log~e~ high-sensitivity C-reactive protein
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See Table [11](#Tab11){ref-type="table"}.Table 11Associations between rs6742078 and confoundersConfoundersβ coefficients (95% CIs)*p* valueAge− 0.05 (− 0.94, 0.85)0.919Male sex− 0.04 (− 0.08, 0.00)0.027Smoking0.00 (− 0.04, 0.04)0.966Systolic blood pressure1.13 (− 0.19, 2.46)0.093Total cholesterol− 0.01 (− 0.09, 0.07)0.855HDL-cholesterol− 0.01 (− 0.04, 0.02)0.353Alcohol consumption− 0.01 (− 0.04, 0.02)0.483Fasting glucose0.00 (− 0.05, 0.06)0.932Estimated GFR0.27 (− 0.87, 1.42)0.638UAE− 0.02 (− 0.08, 0.04)0.561hsCRP− 0.07 (− 0.16, 0.02)0.109Analysis was based on 1610 participants*GFR* glomerular filtration rate, *hsCRP* high-sensitivity C-eactive protein, *UAE* urinary albumin excretion, *HDL* high-density lipoprotein
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